MX2017006536A - Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. - Google Patents
Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.Info
- Publication number
- MX2017006536A MX2017006536A MX2017006536A MX2017006536A MX2017006536A MX 2017006536 A MX2017006536 A MX 2017006536A MX 2017006536 A MX2017006536 A MX 2017006536A MX 2017006536 A MX2017006536 A MX 2017006536A MX 2017006536 A MX2017006536 A MX 2017006536A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- method therefor
- derivatives
- pyridinecarboxamide derivatives
- pharmaceutical uses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se relaciona con los derivados de piridincarboxamida, un método de preparación de los mismos y uso farmacéutico de los mismos. De manera específica, la presente invención se relaciona con derivados de piridincarboxamida representados por la fórmula general (I), en donde los sustituyentes de la fórmula (I) se definen como el mismo que en la descripción, un método de preparación del mismo, una composición farmacéutica que comprende los derivados, y los usos como activos terapéuticos, especialmente como inhibidores del conducto de potasio medular de la franja exterior de los riñones (ROMK) y en la preparación de medicamentos para tratar y/o prevenir la hipertensión e insuficiencia cardiaca. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410741280 | 2014-12-08 | ||
| PCT/CN2015/094164 WO2016091042A1 (zh) | 2014-12-08 | 2015-11-10 | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017006536A true MX2017006536A (es) | 2017-08-09 |
Family
ID=56106663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017006536A MX2017006536A (es) | 2014-12-08 | 2015-11-10 | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. |
| MX2020011818A MX2020011818A (es) | 2014-12-08 | 2017-05-18 | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011818A MX2020011818A (es) | 2014-12-08 | 2017-05-18 | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10364234B2 (es) |
| EP (1) | EP3231802B1 (es) |
| JP (1) | JP6736816B2 (es) |
| KR (1) | KR20170090477A (es) |
| CN (1) | CN105980379B (es) |
| AU (1) | AU2015361614B2 (es) |
| BR (1) | BR112017010645A2 (es) |
| CA (1) | CA2966788A1 (es) |
| MX (2) | MX2017006536A (es) |
| RU (1) | RU2694899C9 (es) |
| TW (1) | TWI718113B (es) |
| WO (1) | WO2016091042A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018012840A (es) | 2016-04-20 | 2019-03-11 | Squibb Bristol Myers Co | Compuestos heterociclicos biciclicos sustituidos. |
| WO2017211271A1 (zh) | 2016-06-07 | 2017-12-14 | 江苏恒瑞医药股份有限公司 | 一种肾外髓质分泌钾通道抑制剂的可药用盐 |
| CN106432071B (zh) * | 2016-09-05 | 2019-04-02 | 河北正朗制药有限公司 | 5-氰基-4-甲氧基-2-吡啶甲酸的盐酸盐的制备及其应用 |
| KR102530512B1 (ko) | 2016-11-03 | 2023-05-08 | 브리스톨-마이어스 스큅 컴퍼니 | Romk 채널 억제제로서 유용한 치환된 비사이클 헤테로시클릭 유도체 |
| CN108113988A (zh) * | 2016-11-29 | 2018-06-05 | 江苏恒瑞医药股份有限公司 | 一种romk抑制剂与arb联合在制备治疗和/或预防高血压或心力衰竭的药物中的用途 |
| AU2018275552B2 (en) | 2017-06-01 | 2022-01-20 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
| WO2019011200A1 (zh) * | 2017-07-10 | 2019-01-17 | 江苏恒瑞医药股份有限公司 | 一种吡啶甲酰胺类衍生物的制备方法及其中间体 |
| US20200347039A1 (en) * | 2017-12-06 | 2020-11-05 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal form of renal outer medullary potassium channel inhibitor and preparation method thereof |
| CN109879863B (zh) * | 2017-12-06 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 |
| TW202045170A (zh) * | 2019-02-28 | 2020-12-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種含有腎臟鉀離子外排通道抑制劑的藥物組合物及其製備方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ585298A (en) * | 2007-11-16 | 2012-08-31 | Rigel Pharmaceuticals Inc | Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| US8673920B2 (en) * | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US9073882B2 (en) | 2010-10-27 | 2015-07-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2012058134A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| CN103874493A (zh) * | 2011-08-19 | 2014-06-18 | 默沙东公司 | 肾外髓质钾通道的抑制剂 |
| US9527830B2 (en) | 2011-09-16 | 2016-12-27 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US8999990B2 (en) | 2011-10-25 | 2015-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2773199B1 (en) | 2011-10-31 | 2019-04-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| AR092031A1 (es) * | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| WO2014015495A1 (en) | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2925322B1 (en) * | 2012-11-29 | 2018-10-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
-
2015
- 2015-11-10 CA CA2966788A patent/CA2966788A1/en not_active Abandoned
- 2015-11-10 US US15/531,525 patent/US10364234B2/en not_active Expired - Fee Related
- 2015-11-10 RU RU2017121460A patent/RU2694899C9/ru active
- 2015-11-10 MX MX2017006536A patent/MX2017006536A/es unknown
- 2015-11-10 AU AU2015361614A patent/AU2015361614B2/en not_active Ceased
- 2015-11-10 EP EP15868279.9A patent/EP3231802B1/en active Active
- 2015-11-10 WO PCT/CN2015/094164 patent/WO2016091042A1/zh active Application Filing
- 2015-11-10 KR KR1020177018177A patent/KR20170090477A/ko not_active Application Discontinuation
- 2015-11-10 JP JP2017528783A patent/JP6736816B2/ja not_active Expired - Fee Related
- 2015-11-10 CN CN201580008517.8A patent/CN105980379B/zh active Active
- 2015-11-10 BR BR112017010645A patent/BR112017010645A2/pt not_active IP Right Cessation
- 2015-12-03 TW TW104140503A patent/TWI718113B/zh active
-
2017
- 2017-05-18 MX MX2020011818A patent/MX2020011818A/es unknown
-
2019
- 2019-01-25 US US16/257,716 patent/US10442794B2/en not_active Expired - Fee Related
- 2019-01-25 US US16/257,484 patent/US10759788B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017536383A (ja) | 2017-12-07 |
| BR112017010645A2 (pt) | 2017-12-26 |
| JP6736816B2 (ja) | 2020-08-05 |
| TWI718113B (zh) | 2021-02-11 |
| WO2016091042A1 (zh) | 2016-06-16 |
| RU2694899C9 (ru) | 2019-08-28 |
| RU2017121460A3 (es) | 2019-03-28 |
| US10759788B2 (en) | 2020-09-01 |
| MX2020011818A (es) | 2021-01-15 |
| CN105980379A (zh) | 2016-09-28 |
| US20190152959A1 (en) | 2019-05-23 |
| CA2966788A1 (en) | 2016-06-16 |
| US10364234B2 (en) | 2019-07-30 |
| CN105980379B (zh) | 2018-09-07 |
| TW201620898A (zh) | 2016-06-16 |
| EP3231802A1 (en) | 2017-10-18 |
| EP3231802A4 (en) | 2018-05-02 |
| RU2694899C2 (ru) | 2019-07-18 |
| RU2017121460A (ru) | 2019-01-10 |
| US10442794B2 (en) | 2019-10-15 |
| AU2015361614B2 (en) | 2019-11-28 |
| KR20170090477A (ko) | 2017-08-07 |
| EP3231802B1 (en) | 2021-05-05 |
| AU2015361614A1 (en) | 2017-06-22 |
| US20170342059A1 (en) | 2017-11-30 |
| US20190152958A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011818A (es) | Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos. | |
| MX2019005379A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
| PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
| EA033266B1 (ru) | Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| MX2016004742A (es) | Derivados de piridil cetona, metodo de preparacion de los mismos, y la aplicacion farmaceutica de los mismos. | |
| PH12016501462A1 (en) | Neprilysin inhibitors | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| PH12017500533A1 (en) | 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators | |
| TW201613578A (en) | Pharmaceutical combinations | |
| GEP20207108B (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| MY181641A (en) | Amino pyran ring derivative and composition and use thereof | |
| TW201613909A (en) | Benzoxazinone amides as mineralocorticoid receptor modulators | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| PH12018502376A1 (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2017002627A (es) | Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak. | |
| MX2017002747A (es) | Derivados de polieteres macrociclicos de n-aril-triciclopirimidin- 2-amino como inhibidores de ftl3 y jak. | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| CA2905957C (en) | Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders | |
| PL410369A1 (pl) | Nowe pochodne peptydowe, sposób ich otrzymywania, kompozycja farmaceutyczna, kompozycja dezynfekująca oraz zastosowanie i zestaw |